Form 8-K - Current report:
SEC Accession No. 0001193125-22-211304
Filing Date
2022-08-03
Accepted
2022-08-03 16:29:03
Documents
14
Period of Report
2022-08-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d304210d8k.htm   iXBRL 8-K 72996
5 GRAPHIC g304210g53g03.jpg GRAPHIC 104603
6 GRAPHIC g304210g61f43.jpg GRAPHIC 81922
  Complete submission text file 0001193125-22-211304.txt   664047

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA pstx-20220803.xsd EX-101.SCH 2845
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE pstx-20220803_lab.xml EX-101.LAB 18738
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pstx-20220803_pre.xml EX-101.PRE 11700
8 EXTRACTED XBRL INSTANCE DOCUMENT d304210d8k_htm.xml XML 3535
Mailing Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-779-3100
Poseida Therapeutics, Inc. (Filer) CIK: 0001661460 (see all company filings)

IRS No.: 472846548 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39376 | Film No.: 221133062
SIC: 2836 Biological Products, (No Diagnostic Substances)